AKE 0.00% $9.83 allkem limited

AKE Chart, page-72

  1. 773 Posts.
    lightbulb Created with Sketch. 1075
    I think many have, just going by the lack of posting here. 90% of posts are now ta graphs, the rest updates on EV developments, there is no fa or specific asset or strategy discussion. Lack of company updates is most likely to blame.

    Pls has outperformed ake, on all fronts sp value creation, execution, strategy, timing, continuity of updates and now cashflow generation.

    Will it continue to do so is anyone's guess, really depends on PLSs downstream success which isn't a given many believe it to be. Producing spodumene alone long term is risky given the abundance of economic resources at +usd500/t and speed of expansion / scalability of some of the larger resources. An oversupply is much more likely in spodumene than further downstream for qualified chemicals imo.

    In the pipeline there is: Liontown 400ktpa+, Core 170ktpa, Mt Holland (sqm/wes) ~400ktpa

    Idle / restart: wodgina 750ktpa + greenbushes cgp2 rampup (~500ktpa)

    Further afield: Avz - which as debatable as it is could turn the spod supply on its head in time (how much time is anyone's guess). Catl has a foot in the door there as well as ganfeng, which doesn't bode well for PLS long term but thats fine they have options.
    North american: pll + sya, nemaska, James Bay ???

    If the WA hydroxide plants are anything to go by, timing slips, capex gets blown out etc etc

    Success of Ake is in their hands, lack of updates doesn't attract the same fanfare pls does. Pls insta posts of teams on site give retail investors the warm fuzzy feeling they are investing in their own people, at home and supporting a greener future. Can't underestimate the importance of being seen to be doing the right thing and being socially accepted, ontop of actually doing it.

    Ake great assets, painfully slow progress across multiple fronts and delays without explanation. Pricing for chemicals worlds apart from the frothy spot pricing in China. Very little to no transparency on counterparties they supply (which has been the main driver of more speculative stocks - announcing offtakes with the battery + EV makers). Ake silent on this front as they are not in charge which is probably as frustrating for them as it is for investors. The naraha product is going to a related party, so can't really expect pricing there to be near open market which amongst other factors contributes to subdued upside.

    Aimo etc etc
 
watchlist Created with Sketch. Add AKE (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.